Precigen(PGEN)
GERMANTOWN, MDBiotechnology
Focus: Precigen is a public cell and gene therapy biotech focused on immunotherapy and gene therapy across oncology, infectious disease, and metabolic disorders. The company operates at modest commercial scale with $6M in FY2025 revenue and maintains a pipeline of early-stage programs.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
11+3 this month
Stable — net +3 jobs in 30d
7 added, 4 removed. Backfill posture.
Should You Work at Precigen?
AI assessmentPrecigen is a high-risk, early-stage gene therapy play with emerging commercial signals but thin cash runway and heavy R&D burn; suitable only for scientists/clinicians comfortable with restructuring risk and seeking equity upside, not stability.
Why Work Here
- Access to emerging gene therapy and CAR-T cell platforms (PRGN-3005 UltraCAR-T, PRGN-3006) at early stage with meaningful upside
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Early-stage
8 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$6M
Key Products
Zopapogene imadenovec
Growing
Peak
First marketed gene therapy product showing strong clinical adoption and driving recent revenue acceleration to projected $18M+ in Q1 2026.
Pipeline & Clinical Trials
Help build intelligence for Precigen
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.